Grand Pharmaceutical Group (FRA:MX6A) Moat Score: 0/10 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MX6A Grand Pharmaceutical Group Ltd FRA:MX6A
86 GF Score
Price €0.57
GF Value €0.63
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grand Pharmaceutical Group Moat Score?

Grand Pharmaceutical Group has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Grand Pharmaceutical Group has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Grand Pharmaceutical Group might have No Moat - No discernible moat.

Grand Pharmaceutical Group  (FRA:MX6A) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Grand Pharmaceutical Group Moat Score Related Terms

FRA:MX6A
86GF Score
Grand Pharmaceutical Group Ltd FRA:MX6A
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?

Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued. The current stock price of €0.57 is trading 10.3% below its estimated GF Value™ of €0.63. GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.

Key valuation signals for FRA:MX6A:

  • Moat Score: 0
  • GF Value™: €0.63 vs. price of €0.57 (10.3% below fair value)
  • GF Score™: 86/100 with 6 warning signs

No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grand Pharmaceutical Group Business Description

Other Exchanges 00512:Hong Kong
Address 99 Queen\'s Road Central, Units 3302, 33rd Floor, The Center, Hong Kong, HKG
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
86GF Score

Get the complete analysis for FRA:MX6A

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.57
Price
€0.63
GF Value